natgillin/translations-raw huggingface dataset:
The review of ambroxol and bromhexine was initiated on 4 April 2014 at the request of Belgium, under Article 31 of Directive 2001/83/EC. 
Pregled ambroksola in bromheksina se je začel 4. aprila 2014 na zahtevo Belgije v skladu s členom 31 Direktive 2001/83/ES.
Frequencies of these side effects are unknown. 
Pogostnost teh neželenih učinkov ni znana.
1 The CMDh is a medicines regulatory body representing the European Union (EU) Member States. 
1 Skupina CMDh je regulativni organ za zdravila, ki zastopa države članice Evropske unije (EU).
The majority of these medicines are available over the counter, whereas some are prescription-only medicines, depending on the condition to be treated and how the treatment is given. 
Večina teh zdravil je na voljo brez recepta, nekatera pa so samo na recept, odvisno od zdravljenega stanja in načina dajanja.
This position was then sent to the European Commission which issued an EU-wide legally binding decision on 14/01/2016. 
Stališče so nato posredovali Evropski komisiji, ki je 14. 1. 2016 izdala končno pravno zavezujočo odločbo za vso EU.
Risk of allergy and skin reactions included in the product information 
Tveganje za alergijo in reakcije na koži vključeno v informacije o zdravilu
As the CMDh position was adopted by majority vote, it was sent to the European Commission, which endorsed it and issued an EU-wide legally binding decision. 
Ker je skupina CMDh svoje stališče sprejela z večino glasov, so ga poslali Evropski komisiji, ki ga je podprla in izdala končno pravno zavezujočo odločbo za vso EU.
Reports of severe allergic reactions and SCARs in patients taking the medicines are rare, and the frequencies of these side effects are unknown. 
Poročila o resnih alergijskih reakcijah in SCAR pri bolnikih, ki jemljejo ta zdravila, so redka, pogostnosti teh neželenih učinkov pa so neznane.
The CMDh first adopted a position by majority vote in February 2015, following which the European Commission requested clarifications on the PRAC recommendation and CMDh position. 
Skupina CMDh je najprej februarja 2015 sprejela stališče z večino glasov, nato pa je Evropska komisija zahtevala pojasnila o priporočilu odbora PRAC in stališču CMDh.
Ambroxol and bromhexine expectorants: safety information updated 
Ekspektoransi z ambroksolom in bromheksidinom: posodobljene informacije o varnosti
A revised CMDh position was subsequently adopted, by majority vote in November 2015. 
Novembra 2015 je bilo z večino glasov sprejeto revidirano stališče skupine CMDh.
Some of these injectable formulations are also used to increase lung development before birth. 
Nekateri izmed teh pripravkov za injiciranje se uporabljajo tudi za pospešitev razvoja pljuč pred rojstvom.
As ambroxol- and bromhexine-containing medicines are all authorised nationally, the PRAC recommendation was forwarded to the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), for a position. 
Ker so vsa zdravila, ki vsebujejo ambroksol in bromheksin, odobrena na nacionalni ravni, so bila priporočila odbora PRAC posredovana Usklajevalni skupini za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v humani medicini (CMDh), ki je morala sprejeti stališče.
• If you are taking ambroxol or bromhexine and have any questions or concerns speak to your doctor of pharmacist. 
• Če jemljete ambroksol ali bromheksin in imate vprašanja ali vas kaj skrbi, se pogovorite z zdravnikom ali farmacevtom.
• If you experience skin reactions such as skin swellings or rash, stop treatment immediately and contact your doctor. 
• Če se pri vas pojavijo kožne reakcije, kot je otekanje kože ali izpuščaj, nemudoma prekinite zdravljenje in se obrnite na svojega zdravnika.
The recommendations were originally made by EMA's Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the previously known risk of allergic reactions and also identified a small risk of SCARs, a group of skin conditions which include erythema multiforme and Stevens-Johnson syndrome. 
Priporočila je prvotno pripravil Odbor za oceno tveganja na področju farmakovigilance (PRAC) agencije EMA, ki je potrdil predhodno znano tveganje za alergijske reakcije in ugotovil manjše tveganje za SCAR, skupino kožnih stanj, ki vključujejo multiformni eritem in Stevens-Johnsonov sindrom.
The medicines are widely available in the EU for use as expectorants (to help clear mucus from the airways). 
Ta zdravila so v EU široko dostopna in se uporabljajo kot ekspektoransi (za pomoč pri čiščenju sluzi iz dihal).
As a result, SCARs are now listed as side effects in the product information for these medicines, and patients are to stop treatment immediately if symptoms of SCARs occur. 
Zato so SCAR zdaj navedeni kot neželeni učinki v informacijah o zdravilu za ta zdravila, bolniki pa morajo v primeru pojava simptomov SCAR zdravljenje nemudoma prekiniti.
Injectable formulations are also used to prevent and treat lung complications following surgery. 
Pripravki za injiciranje se uporabljajo tudi za preprečevanje in zdravljenje zapletov s pljuči po kirurškem posegu.
• Advise your patients that they should stop treatment immediately if symptoms of progressive skin rash occur. 
• Bolnikom svetujte, naj v primeru pojava simptomov napredujočega izpuščaja na koži nemudoma prekinejo zdravljenje.
Ambroxol formulations for injection are also used in premature and newborn babies to treat respiratory distress syndrome, a condition in which the baby's lungs are too immature for the baby to breathe properly. 
Pripravki ambroksola za injiciranje se uporabljajo tudi pri nedonošenčkih in novorojenčkih za zdravljenje sindroma respiratorne stiske, tj. stanja, pri katerem dojenček zaradi nezrelih pljuč ne more pravilno dihati.
On 18 November 2015, the CMDh1 endorsed by majority vote recommendations to update the product information for ambroxol- and bromhexine-containing medicines with information about the small risk of severe allergic reactions and severe cutaneous adverse reactions (SCARs). 
Dne 18. novembra 2015 je skupina CMDh1 z večino glasov podprla priporočila, da se informacije o zdravilu za zdravila, ki vsebujejo ambroksol in bromheksin, posodobijo z informacijami o manjšem tveganju za resne alergijske reakcije in hude kožne neželene učinke (SCAR).
In making the recommendations, the PRAC evaluated available data on ambroxol and bromhexine, including reports of severe allergic reactions or SCARs. 
Pri oblikovanju priporočil je odbor PRAC ovrednotil razpoložljive podatke o ambroksolu in bromheksinu, vključno s poročili o resnih alergijskih reakcijah in SCAR.
Ambroxol- and bromhexine-containing medicines are marketed as single products or as fixed combination products with various other active ingredients. 
Zdravila, ki vsebujejo ambroksol in bromheksin, se tržijo kot samostojna zdravila ali kot zdravila v fiksni kombinaciji z različnimi drugimi zdravilnimi učinkovinami.
EU Member States, and is responsible for ensuring harmonised safety standards for medicines authorised via national procedures across the EU. 
Skupina CMDh je regulativni organ, ki zastopa države članice EU in je odgovorna za zagotavljanje usklajenih varnostnih standardov za zdravila, odobrena po nacionalnih postopkih, po vsej EU.
• As ambroxol is a metabolite of bromhexine, the risk of anaphylactic and severe cutaneous reactions is considered to apply also to bromhexine. 
• Ker je ambroksol presnovek bromheksina, tveganje za anafilaktične in hude kožne reakcije velja tudi za bromheksin.
• The risk of anaphylactic reactions and SCARs with ambroxol or bromhexine is low. 
• Tveganje za anafilaktične reakcije in SCAR pri ambroksolu ali bromheksinu je majhno.
Ambroxol and bromhexine are mainly used by mouth as expectorants to help make the mucus thinner and therefore easier to be cleared away in patients with short- or long-term diseases of the lungs or airways. 
Ambroksol in bromheksin se v glavnem uporabljata peroralno kot ekspektoransa, ki pri bolnikih s kratkotrajnimi ali dolgotrajnimi boleznimi pljuč ali dihal pripomoreta k redčenju in čiščenju sluzi.
• Anaphylactic reactions and severe cutaneous adverse reactions (SCARs), including erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis and acute generalised exanthematous pustulosis, have been reported in patients receiving ambroxol. 
• Pri bolnikih, ki prejemajo ambroksol, so poročali o anafilaktičnih reakcijah in hudih kožnih neželenih učinkih (SCAR), vključno z multiformnim eritemom, Stevens-Johnsonovim sindromom/toksično epidermalno nekrolizo in akutno generalizirano eksantematozno pustulozo.
For ambroxol, lozenge formulations are also available to relieve sore throat. 
Ambroksol je na voljo tudi v obliki pastil za lajšanje bolečega grla.
• There is a small risk of allergy and skin reactions with ambroxol and bromhexine used as expectorants to clear mucus in the airways. 
• Pri ambroksolu in bromheksinu, ki se uporabljata kot ekspektoransa za čiščenje sluzi v dihalih, obstaja majhno tveganje za alergijo in kožne reakcije.
1495-131 Algés, Lisbon Portugal ventilan 
1495-131 Algés, Lisbon
Glaxo Wellcome Farmacêutica, Lda. 
Portugalska Glaxo Wellcome Farmacêutica, Lda.
Torre 3 - 12, 1099-036 Portugal isoxsuprine 
Torre 3 - 12, 1099-036 Portugal isoxsuprine Dilum Retard 30mg tableta s podaljšanim sproščanjem
VENTOLIN®, soluţie injectabilă, 0,5 mg/ml 
VENTOLIN®, soluţie injectabilă, 0,5 mg/ml parenteralna uporaba
Partusisten, concentraat voor oplossing voor intraveneuze infusie 50 microgram/ml 
Partusisten, concentraat voor oplossing voor intraveneuze infusie 50 microgram/ml koncentrat za raztopino za infundiranje
Pharmaceutical forms 
Farmacevtsk a oblika
Ventolin 1mg/ml Concentrate for Solution for Intravenous Infusion 
Ventolin 1mg/ml Concentrate for Solution for Intravenous Infusion koncentrat za raztopino za intravensko infundiranje
Glaxo Wellcome House Berkeley Avenue 
GLAXO WELLCOME UK Limited Glaxo Wellcome House Berkeley Avenue Greenford
Actavis UK Limited Whiddon Valley Barnstaple 
Velika Britanija Actavis UK Limited Whiddon Valley
Ireland AstraZeneca UK Limited 600 Capability Green Luton, LU1 3LU 
Velika Britanija AstraZeneca UK Limited 600 Capability Green
VASOSUPRINA RETARD 
Italy isoxsuprine VASOSUPRINA RETARD
Teva UK Limited Bampton Road Hampden Park Eastbourne 
Velika Britanija Teva UK Limited Bampton Road
Infusionsbereitun g 
Infusionsbereitun g koncentrat za raztopino za infundiranje
SALBUMOL 1 mg, suppository 
SALBUMOL 1 mg, suppository svečka rektalna uporaba
Intravenous use; Intramuscular use 
intravenska uporaba; intramuskularna uporaba
Concentrate for infusion 
koncentrat za raztopino za infundiranje
Sweden AstraZeneca AB SE - 151 85 Södertälje Sweden terbutaline 
AstraZeneca AB SE - 151 85 Södertälje Sweden terbutaline Bricanyl® 0,3mg/ml peroralna raztopina
France AstraZeneca 1, place Renault 92844 Rueil Malmaison Cedex 
1, place Renault 92844 Rueil Malmaison Cedex France terbutaline BRICANYL 0.5 mg/1 ml
SALBUTAMOL MYLAN 5 mg/5 ml, solution for infusion 
SALBUTAMOL MYLAN 5 mg/5 ml, solution for infusion raztopina za infundiranje
SALBUMOL FORT 5 mg / 5 ml solution for infusion 
SALBUMOL FORT 5 mg / 5 ml solution for infusion raztopina za infundiranje
Italy isoxsuprine 
Italy isoxsuprine VASOSUPRINA ILFI
Bricanyl 0,5 mg/ml oldatos injekció 
Hungary terbutaline Bricanyl 0,5 mg/ml oldatos injekció raztopina za injiciranje ali infundiranje
VENTOLIN 2 MG 2mg 
VENTOLIN 2 MG 2mg peroralna raztopinasteklenica
Romania GLAXO WELLCOME UK Limited 
Velika Britanija Glaxo Wellcome UK Limited Stockley Park West
Ventolin 500 micrograms/ml Solution for Injection 
Ventolin 500 micrograms/ml Solution for Injection subkutana, intramuskularna, intravenska uporaba
Bricanyl Syrup 0.3mg/ml 
United Kingdom terbutaline Bricanyl Syrup 0,3mg/ml peroralna raztopina
Solution for injection Intravenous use, Subcutaneous use 
Solution for injection intravenska uporaba, subkutana uporaba
Ventoline 
AstraZeneca
Intramuscular use, Subcutaneous use 
intramuskularna uporaba, subkutana uporaba
VENTOLIN 4MG 4mg 
VENTOLIN 4MG 4mg peroralna raztopina
Austria AstraZeneca Österreich GmbH 
AstraZeneca Österreich GmbH Schwarzenbergplatz 7 A-1037 Vienna
SALBUMOL 0,5 mg/1 ml, solution for injection 
SALBUMOL 0,5 mg/1 ml, solution for injection intravenska uporaba, intramuskularna uporaba, subkutana uporaba
AstraZeneca UK Limited 600 Capability Green Luton, LU1 3LU United Kingdom terbutaline 
AstraZeneca UK Limited 600 Capability Green Luton, LU1 3LU United Kingdom terbutaline Bricanyl 500 micrograms/ml solution for injection or infusion raztopina za injiciranje ali infundiranje subkutana, intramuskularna, intravenska uporaba
Modified-release tablet 
tableta s prirejenim sproščanjem
Pre-Par solution injectable 
Pre-Par solution injectable raztopina za injiciranje ali infundiranje
ATALINE syrup 1.5 mg/5ml 
3505 Lemesos Cyprus terbutaline ATALINE syrup 1.5 mg/5ml sirup
Solution for injection Concentrate for solution for injection 
Partusisten intrapartal koncentrat za raztopino za injiciranje
Partusisten intrapartal 
PRE-PAR AMPOLLAS
Ventolin Solution for Intravenous Infusion 
Ventolin Solution for Intravenous Infusion intravenska uporaba, subkutana uporaba
Takeda Austria GmbH St.-Peter-Straße 25 A -4020 Linz Austria hexoprenaline Gynipral 10 μg / 2 ml - Ampullen 
Takeda Austria GmbH St.-Peter-Straße 25 A -4020 Linz Austria hexoprenaline Gynipral 10 μg / 2 ml - Ampullen raztopina za injiciranje ali infundiranje
NYCOMED Austria GmbH St.-Peter-Straße 25 A -4020 Linz Austria hexoprenaline GYNIPRAL 10 μg/2 ml 
NYCOMED Austria GmbH St.-Peter-Straße 25 A -4020 Linz Austria hexoprenaline GYNIPRAL 10 μg/2 ml parenteralna uporaba
Intravenous use, Intramuscular use, Subcutaneous use 
Ventoline intramuskularna uporaba, subkutana uporaba
Austria terbutaline 
Portugal ventilan
Syrup 
Ciper
Norway AstraZeneca AS Innspurten 15 
AstraZeneca AS Innspurten 15 0663 Oslo Norway terbutaline Bricanyl peroralna raztopina
Always carry some sugar (at least 20 grams) with you. 
Vedno imejte s seboj nekaj sladkorja (vsaj 20 gramov).
Be careful not only when you start another medicine, but also when you stop it. 
Pazite ne samo na to, kdaj začnete jemati drugo zdravilo, ampak tudi na to, kdaj ga prenehate jemati.
Mean GIR (% of Maximum) 
povprečna GIR (% maksimuma)
Your doctor or nurse will have discussed this with you. 
Vaš zdravnik ali medicinska sestra sta se o tem najbrž že pogovorila z vami.
Chamber and mouthpiece - once a week 
Čiščenje Komora in ustnik - enkrat na teden
Do not force, it should easily drop into place. 
Ne uporabljajte sile, nastavek bi moral zlahka zdrsniti na svoje mesto.
However, a recommended starting daily dose is based on the following formula: 
Vendar priporočeni začetni dnevni odmerek temelji na naslednji formuli:
Try always to keep familiar with your warning symptoms. 
Vedno poskušajte natančno prepoznati svoje opozorilne simptome.
Type 1 Diabetes 
Diabetes tipa 1
These symptoms often develop before the symptoms 
Ti simptomi se pogosto razvijejo pred simptomi nizke
These effects are usually transitory. 
Ti učinki so navadno prehodni.
Tell your doctor about all medicines that you are taking, including those you have bought without a prescription (such as from a Pharmacy or other shop). 
Povejte svojemu zdravniku za vsa zdravila, ki jih jemljete, tudi za tista, ki ste jih kupili brez recepta (na primer v lekarni ali kakšni drugi trgovini).
The manufacturer is Heinrich Mack Nachf. 
Izdelovalec je Heinrich Mack Nachf.
These injections may be justified even if it is not 
Te injekcije utegnejo biti upravičene, tudi če niste prepričani, ali imate
Breathe out normally. 
Normalno izdihnite.
What to do in case of hypoglycaemia 
Kaj storiti v primeru hipoglikemije
Do not take more insulin. 
Ne vzemite več insulina.
Check your blood sugar frequently. 
Pogosto preverite svoj krvni sladkor.
Always follow your doctor's instructions about when and how to take EXUBERA. 
Vedno se ravnajte po navodilih svojega zdravnika o tem, kdaj in kako vzeti zdravilo EXUBERA.
Do not block the opening of the mouthpiece with your tongue or teeth. 
Ne zamašite odprtine ustnika z jezikom ali zobmi.
This means that it will start to lower your blood sugar 10-20 minutes after you take it, with a maximum effect at 2 hours and the effect will last for around 6 hours. 
To pomeni, da bo začel zniževati vaš krvni sladkor 10-20 minut po tistem, ko ga vzamete, učinek bo največji po 2 urah in bo trajal okrog 6 ur.
This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery). 
To lahko predstavlja nevarnost v situacijah, v katerih sta ti sposobnosti še posebno pomembni (npr. upravljanje avtomobila ali uporaba strojev).
This change occurs within the first months of treatment and usually doesn't worsen as you continue treatment. 
Ta sprememba se pojavi v prvih mesecih zdravljenja in se med nadaljnjim zdravljenjem ne slabša.
Pharmacotherapeutic group: Medicinal products used in diabetes, ATC code: A10AF01 
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, oznaka ATC: A10AF01
If the hypoglycaemia comes back again take another 10 to 20 gram sugar. 
Če se hipoglikemija ponovi, spet pojejte 10 do 20 gramov sladkorja.
The Marketing Authorisation Holder must implement nationally an educational plan, prior to marketing, and as agreed with the competent authorities in the Member States. 
¾ Imetnik dovoljenja za promet z zdravilom mora pred trženjem na nacionalni ravni uvesti izobraževalni načrt, kot je dogovorjeno s pristojnimi organi v državah članicah.
The majority (> 95%) of these events was reported as mild to moderate. 
Za večino (> 95 %) teh dogodkov so poročali, da so bili blagi do zmerni.
Immediately take about 10 to 20 gram sugar, e.g. as glucose, sugar cubes or a sugar-sweetened drink. 
Nemudoma zaužijte okrog 10 do 20 gramov sladkorja, npr. v obliki glukoze, sladkornih kock ali s sladkorjem oslajene pijače.
Severe allergic reactions to insulin are very rare. 
Hude alergijske reakcije na insulin so zelo redke.
Careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby. 
Natančna urejenost vašega diabetesa in preprečevanje hipoglikemij sta pomembna za zdravje vašega otroka.
Body weight (kg) X 0.15 mg/kg = Total Daily Dose (mg). 
telesna masa (kg) X 0,15 mg/kg = celotni dnevni odmerek (mg).
In order to be able to take action immediately, patients should carry glucose with them at all times. 
Da bi lahko bolniki nemudoma ukrepali, morajo vedno nositi s seboj glukozo.
Produced by recombinant DNA technology in Escherichia coli. 
Izdelano s tehnologijo rekombinantne DNA v bakteriji Escherichia coli.
congestive heart failure, pregnancy, children and adolescent 
kongestivnem srčnem popuščanju, nosečnosti, otrocih in mladostnikih.
In such a case, you may develop severe hypoglycaemia (and even lose consciousness) before you are aware of the problem. 
V takem primeru se utegne pri vas razviti težka hipoglikemija (in celo izguba zavesti), še preden se težave zaveste.
An updated Risk Management Plan, as per the CHMP Guideline on Risk Management Systems for medicinal products for human use, should be submitted at the same time as the PSURs, within 60 days of an important (Pharmacovigilance or Risk minimisation) milestone being reached or when the results of a study becoming available or at the request of the Competent authority. 
Posodobljeni načrt za obvladovanje tveganj (po smernicah CHMP o sistemih za obvladovanje tveganj pri zdravilih za uporabo v humani medicini) mora biti predložen hkrati s PSURi, in sicer v 60 dneh po doseganju kakšnega pomembnega mejnika (farmakovigilanca ali minimizacija tveganja), kadar postanejo dosegljivi rezultati kakšne študije ali na zahtevo pristojnega organa.
There were too few cases to determine whether the emergence of these events is related to Exubera. 
Primerov je bilo premalo, da bi bilo mogoče ugotoviti, ali je njihovo pojavljanje povezano z zdravilom EXUBERA.
If necessary, more frequent blood sugar testing can help to identify mild hypoglycaemic episodes that might otherwise be overlooked. 
Če je potrebno, lahko pogostejše testiranje krvnega sladkorja pomaga prepoznati blage hipoglikemične epizode, ki bi jih utegnili drugače spregledati.
While you are not confident about recognising your warning symptoms, avoid situations (e.g. driving a car) in which you or others would be put at risk by hypoglycaemia. 
Dokler se ne zanesete na to, da boste prepoznali svoje opozorilne simptome, se izogibajte situacijam (npr. vožnji avtomobila), v katerih bi lahko hipoglikemija vas ali druge spravila v nevarnost.
N=Number of Subjects at Baseline, week 52, week 104, week +6, week +12. 
N=število bolnikov v izhodišču, v 52. tednu, v 104. tednu, tednu +6, tednu +12.
No clinical significance of these antibodies has been identified. 
Ugotovili niso nikakršnega kliničnega pomena teh protiteles.
Glucose must also be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes. 
Glukozo moramo dati intravensko tudi takrat, ko bolnik v 10 do 15 minutah ne reagira na glukagon.
Pull out the blue handle as far as it will go. 
Povlecite modro ročico navzven, kolikor daleč gre.
Patients should then hold their breath for 5 seconds and exhale normally. 
Bolniki naj nato zadržijo dih za 5 sekund in normalno izdihnejo.
As with other insulins, generalised allergic reactions may occur very rarely. 
Podobno kot pri drugih insulinih se generalizirane alergijske reakcije pojavljajo zelo redko.
Ensure that no water droplets remain, and then close the mouthpiece. 
Prepričajte se, da ni več vodnih kapljic, nato ustnik zaprite.
Insulin requirements may be altered during intercurrent conditions such as illness, emotional 
Potrebe po insulinu se lahko spremenijo med interkurentnimi stanji, na primer boleznimi, čustvenimi
Be sure that the word “EXUBERA” at the top faces you. 
Prepričajte se, da je beseda “EXUBERA” na vrhu obrnjena proti vam.
The total daily dose should be divided into three pre-meal doses. 
Celotni dnevni odmerek je treba razdeliti v tri odmerke, ki se dajejo pred obroki.
When used with other antidiabetic agents, the dose of each agent should be carefully adjusted to determine the optimal dose required to achieve the desired pharmacological effect. 
Kadar to zdravilo uporabljamo skupaj z drugimi antidiabetiki, je treba odmerek vsakega zdravila skrbno prilagoditi, da določite optimalni odmerek, ki je potreben za dosego želenega farmakološkega
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. 
Težki napadi hipoglikemije, posebno še, če se ponavljajo, lahko povzročijo nevrološke okvare.
EXUBERA is available in the following pack sizes: 
Zdravilo EXUBERA je na voljo v naslednjih velikostih pakiranja:
Some medicines cause the blood sugar level to fall, some cause it to rise, others may have both effects, depending on the situation. 
Nekatera zdravila povzročijo zvišanje, druga pa znižanje koncentracije krvnega sladkorja; tretja imajo lahko oba učinka, odvisno od situacije.
It is important to follow these steps so that your insulin inhaler stays clean and works properly. 
Pomembno je, da se ravnate po teh navodilih, tako da bo insulinski inhalator vedno čist in bo pravilno deloval.
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan. 
Imetnik dovoljenja za promet se zavezuje, da bo izvedel študije in dodatne farmakovigilančne dejavnosti, razčlenjene v načrtu farmakovigilance.
After first opening the foil overwrap: 3 months. 
Po prvem odprtju prekrivne folije: 3 mesece.
These changes are usually mild and go away with time. 
Te spremembe so navadno blage in sčasoma izginejo.
If at 6 months a decline of < 15% FEV1 is observed, spirometry should be repeated at one year and then annually. 
Če je po 6 mesecih opazno zmanjšanje FEV1 < 15 %, je treba spirometrijo ponoviti čez eno leto in nato enkrat na leto.